



**RaQualia**  
innovators for life

**Acid Pump Antagonist (APA) for  
Acid-related diseases**  
**Worldwide Partnering Opportunity**

# 1. Executive Summary

- RQ-00000004 is a novel gastric acid pump antagonist with efficacy superior to current proton pump inhibitor (PPI) therapies
  - Rapid onset
  - Long duration
  - No food effect
  - Effective on nocturnal symptom
- First in human study of RQ-00000004 is ongoing in the US
  - No critical safety issue
  - PD biomarker result will be disclosed under CDA
- RQ-00000004 is one of the most advanced APAs for GERD
  - TAK-438 (Takeda Phase 2 in Japan) and Revaprazan\* (Yuhan Phase 3 in Korea)
- Partnering opportunity for worldwide development & commercial rights
  - RQ-00000004 & backup development candidate
  - Except the rights in Korea and China: out-licensed to CJ CheilJedang in 2010

\*; Market for ulcer treatment in Korea

## 2. Table of Contents

Title	Slide No.
1. Table of Contents	2
2. Executive Summary	3
3. GERD and Current Therapies	4
4. Unmet Medical Needs in GERD	5
5. Regulation of Acid Secretion	6
6. Pharmacology of PPI and APA	7
7. Mode of Action and APA profile	9
7.1. Fast onset of action	11
7.2. Long duration of action	12
7.3. Superior potency	13
7.4. No food effect	14
7.5. Efficacy on nocturnal symptoms	15
8. Target Product Profile	16
9. Advantages of APA in Other Indications of PPIs	17
10. Compound Attributes	18
10.1. <i>In vitro</i> pharmacology	19
10.2. Non-clinical pharmacology of RQ-00000004	20
10.3. Non-clinical DMPK	26
10.4. Non-clinical safety	28
10.5. First in human study	29
10.6. Summary of RQ-00000004	31
11. Competitors in APA Field	32

弊社とのパートナーリングをご希望の方は「[お問い合わせ](#)」よりご連絡ください

**ラクオリア創薬株式会社**

Copyright RaQualia Pharma Inc. All Rights Reserved. 2011